Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00719563 · ClinicalTrials.gov registry record · Phase 3
American Ginseng in Treating Patients With Fatigue Caused by Cancer
A Phase 3 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 3
- Development phase
- 364
- Enrollment target
NCT00719563 is a Phase 3 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 364 participants.
The verdict
NCT00719563, a Phase 3 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 364 participants
- Enrollment target
Study Summary
RATIONALE: American ginseng may reduce fatigue in patients with cancer. It is not yet known whether American ginseng is more effective than a placebo in treating cancer-related fatigue. PURPOSE: This randomized phase III trial is studying American ginseng to see how well it works in treating patients with fatigue caused by cancer.
Interventions
- OTHER placebo
- DRUG American ginseng
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 364 participants |
| Start Date | 2008-10 |
| Est. Completion | 2013-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00719563
The ClinicalTrials.gov registry entry for NCT00719563 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 364 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00719563 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00719563 about?
NCT00719563 is a clinical study titled "American Ginseng in Treating Patients With Fatigue Caused by Cancer". RATIONALE: American ginseng may reduce fatigue in patients with cancer. It is not yet known whether American ginseng is more effective than a placebo in treating cancer-related fatigue. PURPOSE: This randomized phase III trial is studying American ginseng to see how well it works in treating patien...
What is the current status of trial NCT00719563?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 364 participants. The study started on 2008-10. Estimated completion is 2013-08.
What interventions are being tested in trial NCT00719563?
The interventions under investigation include: placebo (OTHER), American ginseng (DRUG).
Who is sponsoring clinical trial NCT00719563?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.